NCT00004393View on ClinicalTrials.gov

Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 1997

Study Completion Date

September 30, 2000

Conditions
Tourette Syndrome
Interventions
DRUG

risperidone

All Listed Sponsors
collaborator

Yale University

OTHER

lead

National Center for Research Resources (NCRR)

NIH

NCT00004393 - Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome | Biotech Hunter | Biotech Hunter